OtherClinical Practice Guidelines
Open Access

The use of progesterone during pregnancy to prevent preterm birth

Eman S. Alsulmi, Malikah Alfaraj, Yaser Faden and Noura Al Qahtani
Saudi Medical Journal April 2020, 41 (4) 333-340; DOI: https://doi.org/10.15537/smj.2020.4.25036

References

  1. ↵
    1. World Health Organization. WHO recommended definitions, terminology and format for statistical tables related to the perinatal period and use of a new certificate for cause of perinatal deaths. Modifications recommended by FIGO as amended October 14
    (1976) Acta Obstetricia Et Gynecologica Scandinavica 1977(56):247–253.
    OpenUrl
  2. ↵
    1. Blencowe H,
    2. Cousens S,
    3. Oestergaard MZ,
    4. Chou D,
    5. Moller AB,
    6. Narwal R,
    7. et al.
    (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries:a systematic analysis and implications. Lancet 379:2162–2172.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. World Health Organization
    Country data and rankings for preterm birth data EMBARGO until May 2nd 2012, [cited 2012], Available from: https://www.who.int/pmnch/media/news/2012/201204_borntoosoon_countryranking.pdf.
  4. ↵
    1. UNICEF. Saudi Arabia
    (2012) Maternal, Newborn &Child Survival (Statistics and Monitoring Section/Policy and Practice, Saudi Arabia (KSA)) [cited 2012], Available from: https://data.unicef.org/wp-content/uploads/country_profiles/Saudi%20Arabia/Maternal_SAU.pdf.
  5. ↵
    1. Blanks AM,
    2. Brosens JJ
    (2012) Progesterone action in the myometrium and decidua in preterm birth. Facts Views Vis Obgyn 4:33–43.
    OpenUrlPubMed
  6. ↵
    1. Xu H,
    2. Gonzalez JM,
    3. Ofori E,
    4. Elovitz MA
    (2008) Preventing cervical ripening:the primary mechanism by which progestational agents prevent preterm birth? Am J Obstet Gynecol 198:314, e1–e8.
    OpenUrlPubMed
    1. Nold C,
    2. Maubert M,
    3. Anton L,
    4. Yellon S,
    5. Elovitz MA
    (2013) Prevention of preterm birth by progestational agents:what are the molecular mechanisms? Am J Obstet Gynecol 208:223, e1–e7.
    OpenUrl
    1. Kirby MA,
    2. Heuerman AC,
    3. Custer M,
    4. et al.
    (2016) Progesterone receptor-mediated actions regulate remodeling of the cervix in preparation for preterm parturition. Reprod Sci 23:1473–1483.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Yellon SM
    (2017) Contributions to the dynamics of cervix remodeling prior to term and preterm birth. Biol Reprod 96:13–23.
    OpenUrlCrossRef
  10. ↵
    1. Zakar T,
    2. Mesiano S
    (2011) How does progesterone relax the uterus in pregnancy? N Engl J Med 364:972–973.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Norman JE,
    2. Marlow N,
    3. Messow C-M,
    4. Shennan A,
    5. Bennett PR,
    6. Thornton S,
    7. et al.
    (2016) Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study):a multicenter, randomized, double-blind trial. Lancet 387:2106–2116.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Northen AT,
    2. Norman GS,
    3. Anderson K,
    4. Moseley L,
    5. Divito M,
    6. Cotroneo M,
    7. et al.
    (2007) Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 110:865–872.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Hauth JC,
    2. Gilstrap LC III.,
    3. Brekken AL,
    4. Hauth JM
    (1983) The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 146:187–190.
    OpenUrlPubMedWeb of Science
  14. ↵
    1. Committee on Practice Bulletins-Obstetrics TACoO, Gynecologists. Practice bulletin no.130:prediction and prevention of preterm birth
    (2012) Obstet Gynecol 120:964–973.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Grobman WA
    (2012) for the Eunice Kennedy Shriver National Institute of Health and Human Development. Randomized controlled trial of progesterone treatment for preterm birth prevention in nulliparous women with cervical length less than 30mm. Am J Obstet Gynecol 206:s367.
    OpenUrl
  16. ↵
    1. O'Brien JM,
    2. Adair CD,
    3. Lewis DF,
    4. Hall DR,
    5. Defranco EA,
    6. Fusey S,
    7. et al.
    (2007) Progesterone vaginal gel for the reduction of recurrent preterm birth:primary results from a randomized, double-blind, placebo controlled trial. Ultrasound Obstet Gynecol 30:687–696.
    OpenUrlCrossRefPubMedWeb of Science
    1. Fonseca EB,
    2. Celik E,
    3. Parra M,
    4. Singh M,
    5. Nicolaides KH
    (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357:462–469.
    OpenUrlCrossRefPubMedWeb of Science
    1. Hassan SS,
    2. Romero R,
    3. Vidyadhari D,
    4. Fusey S,
    5. Baxter JK,
    6. Khandelwal M,
    7. et al.
    (2011) Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix:a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 38:18–31.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Romero R,
    2. Nicolaides K,
    3. Conde-Agudelo A,
    4. Tabor A,
    5. O'Brien JM,
    6. Cetingoz E,
    7. et al.
    (2012) Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity:a systematic review and meta-analysis of individual patient data. Am J Obstet Gynecol 206:124.e1–124.e19.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Romero R,
    2. Nicolaides KH,
    3. Conde-Agudelo A,
    4. O'Brien JM,
    5. Cetingoz E,
    6. Fonseca E,
    7. et al.
    (2016) Vaginal progesterone decreases preterm birth <34 weeks of gestation in women with a singleton pregnancy and a short cervix:an updated meta-analysis including data from the OPPTIMUM study. Ultrasound Obstet Gynecol 48:380–317.
    OpenUrl
  21. ↵
    1. Romero R,
    2. Fonseca EB,
    3. O'Brien JM,
    4. Nicolaides K,
    5. et al.
    (2018) Vaginal progesterone to prevent preterm birth in singleton gestations with a short cervix. Am J Obstet Gynecol 218:162–180.
    OpenUrl
  22. ↵
    1. Dodd JM,
    2. Crowther CA,
    3. Cincotta R,
    4. Flenady V,
    5. Robinson JS
    (2005) Progesterone supplementation for preventing preterm birth:a systematic review and meta-analysis. Acta Obstet Gynecol Scand 84:526–533.
    OpenUrlCrossRefPubMedWeb of Science
    1. Sanchez-Ramos L,
    2. Kaunitz AM,
    3. Delke I
    (2005) Progestational agents to prevent preterm birth:a meta-analysis of randomized controlled trials. Obstet Gynecol 105:273–279.
    OpenUrlCrossRefPubMedWeb of Science
    1. Coomarasamy A,
    2. Thangaratinam S,
    3. Gee H,
    4. Khan KS
    (2006) Progesterone for the prevention of preterm birth:a critical evaluation of evidence. Eur J Obstet Gynecol Reprod Biol 129:111–118.
    OpenUrlCrossRefPubMed
    1. Mackenzie R,
    2. Walker M,
    3. Armson A,
    4. Hannah ME
    (2006) Progesterone for the prevention of preterm birth among women at increased risk:a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 194:1234–1242.
    OpenUrlCrossRefPubMedWeb of Science
    1. Dodd JM,
    2. Flenady VJ,
    3. Cincotta R,
    4. Crowther CA
    (2008) Progesterone for the prevention of preterm birth:a systematic review. Obstet Gynecol 112:127–134.
    OpenUrlCrossRefPubMedWeb of Science
    1. Dodd JM,
    2. Jones L,
    3. Flenady V,
    4. Cincotta R,
    5. Crowther CA
    (2013) Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev 7:CD004947.
    OpenUrlPubMed
    1. Likis FE,
    2. Edwards DR,
    3. Andrews JC,
    4. Woodworth AL,
    5. Jerome RN,
    6. Fonnesbeck CJ,
    7. et al.
    (2012) Progestogens for preterm birth prevention:a systematic review and meta-analysis. Obstet Gynecol 120:897–907.
    OpenUrlCrossRefPubMedWeb of Science
    1. Majhi P,
    2. Bagga R,
    3. Kalra J,
    4. Sharma M
    (2009) Intravaginal use of natural micronised progesterone to prevent pre-term birth:a randomized trial in India. J Obstet Gynaecol 29:493–498.
    OpenUrlPubMed
  30. ↵
    1. Meis PJ,
    2. Klebanoff M,
    3. Thom E,
    4. Dombrowski MP,
    5. Sibai B,
    6. Moawad AH,
    7. et al.
    (2003) Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348:2379–2385.
    OpenUrlCrossRefPubMedWeb of Science
    1. O'Brien JM,
    2. Adair CD,
    3. Lewis DF,
    4. Hall DR,
    5. Defranco EA,
    6. Fusey S,
    7. et al.
    (2007) Progesterone vaginal gel for the reduction of recurrent preterm birth:primary results from a randomized, double-blind, placebo controlled trial. Ultrasound Obstet Gynecol 30:687–696.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    1. Rai P,
    2. Rajaram S,
    3. Goel N,
    4. Ayalur Gopalakrishnan R,
    5. Agarwal R,
    6. Mehta S
    (2009) Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 104:40–43.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Elimian A,
    2. Smith K,
    3. Williams M,
    4. Knudtson E,
    5. Goodman JR,
    6. Escobedo MB
    (2016) A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth. Int J Gynaecol Obstet 134:169–172.
    OpenUrl
    1. Bafghi AS,
    2. Bahrami E,
    3. Sekhavat L
    (2015) Comparative study of vaginal versus intramuscular progesterone in the prevention of preterm delivery:a randomized clinical trial. Electron Physician 7:1301–1309.
    OpenUrl
  35. ↵
    1. Maher MA,
    2. Abdelaziz A,
    3. Ellaithy M,
    4. Bazeed MF
    (2013) Prevention of preterm birth:a randomized trial of vaginal compared with intramuscular progesterone. Acta Obstet Gynecol Scand 92:215–222.
    OpenUrl
  36. ↵
    1. Saccone G,
    2. Khalifeh A,
    3. Elimian A,
    4. et al.
    (2017) Vaginal progesterone compared to intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations:a systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol 49:315–321.
    OpenUrl
  37. ↵
    1. da Fonseca EB,
    2. Bittar RE,
    3. Carvalho MH,
    4. Zugaib M
    (2003) Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk:a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 188:419–424.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Johnson JW,
    2. Austin KL,
    3. Jones GS,
    4. Davis GH,
    5. King TM
    (1975) Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 293:675–680.
    OpenUrlCrossRefPubMedWeb of Science
  39. ↵
    1. Blackwell SC,
    2. Gyamfi-Bannerman C,
    3. Biggio JR Jr.,
    4. Chauhan SP,
    5. Hughes BL,
    6. Louis JM,
    7. et al.
    (2020) 17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study):a multicenter, international, randomized double-blind trial. Am J Perinatol 37:127–136.
    OpenUrlCrossRef
  40. ↵
    1. Fonseca EB,
    2. Celik E,
    3. Parra M,
    4. Singh M,
    5. Nicolaides KH
    (2007) Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357:462–469.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Hassan SS,
    2. Romero R,
    3. Vidyadhari D,
    4. Fusey S,
    5. Baxter JK,
    6. Khandelwal M,
    7. et al.
    (2011) PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix:a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 38:18–31.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. Romero R,
    2. Fonseca EB,
    3. O'Brien JM,
    4. Nicolaides K,
    5. et al.
    (2018) Vaginal progesterone to prevent preterm birth in singleton gestations with a short cervix. Am J Obstet Gynecol 218:162–180.
    OpenUrl
  43. ↵
    1. Berghella V,
    2. Figueroa D,
    3. Szychowski JM,
    4. Owen J,
    5. Hankins GD,
    6. Iams JD,
    7. et al.
    (2010) 17-Alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 202:351.e1–351.e6.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Conde-Agudelo A,
    2. Romero R,
    3. Nicolaides K,
    4. Chaiworapongsa T,
    5. O'Brien JM,
    6. Cetingoz E,
    7. et al.
    (2013) Vaginal progesterone vs. cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation:a systematic review and indirect comparison meta-analysis. Am J Obstet Gynecol 208:42.e1–42.e18.
    OpenUrl
  45. ↵
    1. Rouse DJ,
    2. Caritis SN,
    3. Peaceman AM,
    4. Sciscione A,
    5. Thom EA,
    6. Spong CY,
    7. et al.
    (2007) A trial of 17 alpha-Hydroxyprogesterone carporate to prevent prematurity in twins. N Engl J Med 357:454–461.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Combs CA,
    2. Garite T,
    3. Maurel K,
    4. Das A,
    5. Porto M
    (2011) Obstetrix Collaborative Research Network. 17-hydroxyprogesterone carpoate for twin pregnancy:a double-blind, randomized clinical trial. Am J Obstet Gynecol 204:221.e1–221.e8.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Awwad J,
    2. Usta IM,
    3. Ghazeeri G,
    4. Yacoub N,
    5. Succar J,
    6. Hayek S,
    7. et al.
    (2015) A randomized controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN):evidence for reduced neonatal morbidity. BJOG 122:71–79.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Caritis SN,
    2. Rouse DJ,
    3. Peaceman AM,
    4. Sciscione A,
    5. Momirova V,
    6. Spong CY,
    7. et al.
    (2009) Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate:a randomized controlled trial. Obstet Gynecol 113:285–292.
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Combs CA,
    2. Garite T,
    3. Maurel K,
    4. Das A,
    5. Porto M
    (2010) Obstetrix Collaborative Research Network. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy:a double-blind, randomized clinical trial. Am J Obstet Gynecol 203:e241–e249.
    OpenUrlCrossRef
  50. ↵
    1. Durnwald CP1,
    2. Momirova V,
    3. Rouse DJ,
    4. Caritis SN,
    5. Peaceman AM,
    6. Sciscione A,
    7. et al.
    (2010) Eunice Kennedy Shriver National Institute of Child Health and Human cDevelopment Maternal-Medicine Units Network. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-alpha hydroxyprogesterone carpoate. J Matern Fetal Neonatal Med 23:1360–1364.
    OpenUrlCrossRefPubMedWeb of Science
  51. ↵
    1. Senat MV,
    2. Porcher R,
    3. Winer N,
    4. Vayssière C,
    5. Deruelle P,
    6. Capelle M,
    7. et al.
    (2013) Groupe de Recherche en Obstet st Gynecol. Prevention of preterm delivery by 17 alpha-hydroxyprogesterone carpoate in asymptomatic twin pregnancies with a short cervix:a randomized controlled trial. Am J Obstet Gynecol 208:194.e1–194.e8.
    OpenUrl
  52. ↵
    1. O'Brein JM
    (2013) Mortality related to 17-OHPC exposure is an important safety outcome. Am J Obstet Gynecol 209:282–283.
    OpenUrl
  53. ↵
    1. Lim AC,
    2. Schuit E,
    3. Bloemenkamp K,
    4. Bernardus RE,
    5. Duvekot JJ,
    6. Erwich JJ,
    7. et al.
    (2011) 17?-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies:a randomized controlled trial. Obstet Gynecol 118:513–520.
    OpenUrlCrossRefPubMedWeb of Science
  54. ↵
    1. Norman JE,
    2. Mackenzie F,
    3. Owen P,
    4. Mactier H,
    5. Hanretty K,
    6. Cooper S,
    7. et al.
    (2009) Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT):a randomized, double-blind, placebo-controlled study and meta-analysis. Lancet 373:2034–2040.
    OpenUrlCrossRefPubMedWeb of Science
    1. Rode L,
    2. Klein K,
    3. Nicolaides KH,
    4. Krampl-Bettelheim E,
    5. Tabor A
    (2011) PREDICT Group. Prevention of preterm delivery in twins gestations ( PREDICT):a multicenter, randomized, placebo-controlled trial on the effect of vaginal micronized progesterone. Ultrasound Obstet Gynecol 38:272–280.
    OpenUrlPubMedWeb of Science
  56. ↵
    1. Brizot ML,
    2. Hernandez W,
    3. Liao AW,
    4. Bittar RE,
    5. Francisco RPV,
    6. Krebs VLJ,
    7. et al.
    (2015) Vaginal progesterone for the prevention of preterm birth in twin gestations:a randomized placebo-controlled double blind study. Am J Obstet Gynecol 213:82.e1–82.e9.
    OpenUrl
  57. ↵
    1. Klein K,
    2. Rode L,
    3. Nicolaides KH,
    4. Krampl-Bettelheim E,
    5. Tabor A
    (2011) PREDICT Group. Vaginal micronized progesterone and risk of preterm delivery in high risk twin pregnancies:secondary analysis of a placebo- controlled randomized trial and meta-analysis. Ultrasound Obstet Gynecol 38:281–287.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Romero R,
    2. Nicolaides K,
    3. Conde-Agudelo A,
    4. Tabor A,
    5. O'Brien JM,
    6. Cetingoz E,
    7. et al.
    (2012) Vaginal progesterone in women with an asymptomatic sonographic short cervix in the mid trimester decreases preterm delivery and neonatal morbidity:a systemic review and meta-analysis of individual patient data. Am J Obstet Gynecol 206:124.e1–124.e19.
    OpenUrlCrossRefPubMed
    1. Schuit E,
    2. Stock S,
    3. Rode L,
    4. Rouse DJ,
    5. Lim AC,
    6. Norman JE,
    7. et al.
    (2015) Effectiveness of progesterone to improve perinatal outcome in twin pregnancies :an individual participant data meta-analysis. BJOG 122:27–37.
    OpenUrlCrossRefPubMed
  60. ↵
    1. El-Refaie W,
    2. Abdelhafez MS,
    3. Badawy A
    (2016) Vaginal Progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix:a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet 293:61–67.
    OpenUrl
  61. ↵
    1. Romero R,
    2. Conde-Agudelo A,
    3. El-Refaie W6,
    4. Rode L,
    5. Brizot ML,
    6. Cetingoz E,
    7. et al.
    (2017) Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix:an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol 49:303–314.
    OpenUrlCrossRef
  62. ↵
    1. Quist-Nelson J,
    2. Parker P,
    3. Mokhtari N,
    4. Di Sarno R,
    5. Saccone G,
    6. Berghella V
    (2018) Progestogens in singleton gestations with preterm prelabor rupture of membranes:a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 219:346–355.
    OpenUrl
  63. ↵
    1. Su LL,
    2. Samuel M,
    3. Chong YS
    (2014) Progestational agents for treating threatened or established preterm labour. Cochrane Database Syst Rev 1:CD006770.
    OpenUrl
  64. ↵
    1. Gonzalez-Quintero VH,
    2. Istwan NB,
    3. Rhea DJ,
    4. Smarkusky L,
    5. Hoffman MC,
    6. Stanziano GJ
    (2007) Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery. J Matern Fetal Neonatal Med 20:249–252.
    OpenUrlPubMed
  65. ↵
    1. How HY,
    2. Barton JR,
    3. Istwan NB,
    4. Rhea DJ,
    5. Stanziano GJ
    (2007) Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery:does gestational age at initiation of treatment matter? Am J Obstet Gynecol 197:260.e1–260.e4.
    OpenUrlPubMed
  66. ↵
    1. Rebarber A,
    2. Ferrara LA,
    3. Hanley ML,
    4. Istwan NB,
    5. Rhea DJ,
    6. Stanziano GJ,
    7. et al.
    (2007) Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 196:224.e1–224.e4.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords